Sector Investors News and Insights

GSK

Could this AI growth stock, backed by Google, become the next Nvidia?

A healthcare company called Tempus AI (NASDAQ: TEM) that utilizes artificial intelligence (AI) to assist doctors in customizing patient care became a publicly traded company on 14 June. Established in 2015…

Could this AI growth stock, backed by Google, become the next Nvidia? Read More »

, , , , , , , , , , ,

A Google-supported artificial intelligence growth stock could be the next Nvidia.

On June 14, Tempus AI (NASDAQ: TEM), a healthcare company that utilizes artificial intelligence to assist doctors in customizing patient care, went public as a promising new growth stock. Established in 2015…

A Google-supported artificial intelligence growth stock could be the next Nvidia. Read More »

, , , , , , , , , , ,

Could this AI growth stock supported by Google be the next Nvidia?

Tempus AI, a healthcare company utilizing artificial intelligence to assist doctors in customizing patient care, became a publicly traded stock on June 14th. Established in 2015…

Could this AI growth stock supported by Google be the next Nvidia? Read More »

, , , , , , , , , , ,

Morning Brew reports on NIO’s revenue decline, Novavax’s gains in response to FDA review, and GSK’s acquisition of Elsie Biotech.

Stocks that are related include AAPL, NVAX, NIO, GSK, NVDA, MSFT, VNDA, IREN, MCRB, SMG, CORZ, with a 0.6% increase in HONGKONG’S HANG SENG.

Morning Brew reports on NIO’s revenue decline, Novavax’s gains in response to FDA review, and GSK’s acquisition of Elsie Biotech. Read More »

, , , ,

Morning Brew summarizes the latest news: NIO has reported a decrease in revenue, Novavax’s stock price is up following an FDA review, and GSK announces the acquisition of Elsie Biotech.

Stocks that are related include AAPL, NVAX, NIO, GSK, NVDA, MSFT, VNDA, IREN, MCRB, SMG, and CORZ, with a 0.6% increase in HONGKONG’S HANGSENG.

Morning Brew summarizes the latest news: NIO has reported a decrease in revenue, Novavax’s stock price is up following an FDA review, and GSK announces the acquisition of Elsie Biotech. Read More »

, , , ,
Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com